LU AF36201

LU AF36201 is an experimental pharmaceutical compound developed by Lundbeck. It has been studied primarily as a metabolite in pharmacokinetic interactions, especially in the context of drug-drug interaction studies involving LU AF11167 and itraconazole. LU AF36201 is not the primary therapeutic agent but rather appears as a measured metabolite in these studies. Its mechanism of action, clinical development, and therapeutic relevance as a stand-alone drug entity are not established in publicly available literature. It has not been reported in efficacy or safety trials as a primary drug candidate in any human disease.